PRISM BioLab Co. LTD (JP:206A)
:206A
Want to see JP:206A full AI Analyst Report?
Top Page
PRISM BioLab Co. LTD
(206A)
Select Model
Select Model
Rating:44Neutral
Price Target:
¥132.00
▼(-17.50% Downside)
Action:Reiterated
Date:06/09/26
The score is held down primarily by persistent losses and deteriorating/free cash flow trends, indicating elevated funding and execution risk. Technicals also remain bearish with the stock trading below all key moving averages and negative MACD. A negative P/E (loss-making) and no dividend data further limit valuation support.
Positive Factors
Debt-free balance sheet
Zero reported debt materially lowers refinancing and interest risks, giving management flexibility to allocate cash to R&D, partnerships or pivots without fixed interest burdens. For a biotech with long development cycles this reduces solvency risk over the next few quarters.
Negative Factors
Persistent unprofitability
Recurring, sizable negative EBIT and net losses across 2023–2025 signal the business is not yet operationally profitable. Persistent losses elevate reliance on external capital, increase dilution risk and heighten execution pressure for clinical and commercial milestones over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt materially lowers refinancing and interest risks, giving management flexibility to allocate cash to R&D, partnerships or pivots without fixed interest burdens. For a biotech with long development cycles this reduces solvency risk over the next few quarters.
Read all positive factors
PRISM BioLab Co. LTD (206A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.81B
Dividend YieldN/A
Average Volume (3M)2.26M
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth74.13%
EPS Growth22.94%
CountryJP
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.60
Shares Outstanding36,964,000
10 Day Avg. Volume1,556,930
30 Day Avg. Volume2,256,993
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.27
Price to Sales (P/S)9.06
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PRISM BioLab Co. LTD Business Overview & Revenue Model
Company Description
PRISM Pharma Co., Ltd. is a pharmaceutical enterprise dedicated to identifying and advancing small molecule compounds. Its core mission involves modulating protein-protein interactions. The company leverages a proprietary protein secondary structu...
How the Company Makes Money
null...
PRISM BioLab Co. LTD Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 677.33M | 305.62M | 112.93M | 554.40M |
| Gross Profit | 269.76M | 160.54M | 80.31M | 535.14M |
| EBITDA | -831.28M | -1.05B | -488.13M | 67.89M |
| Net Income | -833.70M | -1.05B | -526.91M | 72.96M |
Balance Sheet | ||||
| Total Assets | 3.09B | 4.53B | 1.21B | 1.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.92B | 4.39B | 1.13B | 1.69B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 376.86M | 1.03B | 63.41M | 65.23M |
| Stockholders Equity | 2.71B | 3.50B | 1.15B | 1.67B |
Cash Flow | ||||
| Free Cash Flow | -1.53B | -61.55M | -548.40M | 97.25M |
| Operating Cash Flow | -1.47B | 150.14M | -513.81M | 102.96M |
| Investing Cash Flow | -69.01M | -244.19M | -40.38M | -7.87M |
| Financing Cash Flow | 33.59M | 3.37B | 0.00 | 110.87M |
PRISM BioLab Co. LTD Technical Analysis
Negative
160.00
Price Trends
163.50
Negative
178.55
Negative
174.02
Negative
Market Momentum
-8.60
Negative
32.19
Neutral
48.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:206A, the sentiment is Negative. The current price of 160 is above the 20-day moving average (MA) of 139.70, below the 50-day MA of 163.50, and below the 200-day MA of 174.02, indicating a bearish trend. The MACD of -8.60 indicates Negative momentum. The RSI at 32.19 is Neutral, neither overbought nor oversold. The STOCH value of 48.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:206A.
PRISM BioLab Co. LTD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥6.23B | 86.18 | ― | 1.24% | -7.13% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥25.67B | -35.15 | ― | ― | -11.11% | -187.80% | |
49 Neutral | ¥18.80B | -10.30 | ― | ― | ― | 6.10% | |
44 Neutral | ¥4.81B | -5.26 | ― | ― | 74.13% | 22.94% | |
42 Neutral | ¥12.35B | -20.34 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.22B | -8.45 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:206A
PRISM BioLab Co. LTD
130.00
-108.00
-45.38%
JP:4599
StemRIM Inc.
300.00
-22.00
-6.83%
JP:4880
CellSource Co., Ltd.
314.00
-369.14
-54.04%
JP:4978
ReproCELL Inc.
126.00
-43.00
-25.44%
JP:7774
Japan Tissue Engineering Co., Ltd.
632.00
27.00
4.46%
JP:7776
CellSeed Inc.
210.00
-277.00
-56.88%
PRISM BioLab Co. LTD Corporate Events
PRISM BioLab to End Drug Discovery Library Agreement with Boehringer Ingelheim
May 15, 2026
PRISM BioLab announced that its research and license agreement with German pharmaceutical group Boehringer Ingelheim International will end on May 16, 2026, upon completion of the originally agreed contractual term. Under the collaboration, PRISM ...
PRISM BioLab Widens Interim Loss, Cuts Equity and Withholds Full-Year Outlook
May 14, 2026
PRISM BioLab reported non-consolidated revenue of ¥253 million for the six months to March 31, 2026, a 15.8% year-on-year increase, but the company remained loss-making with a net loss of ¥603 million and basic loss per share of ¥16...
PRISM BioLab and Receptor.AI Team Up on AI-Driven Small-Molecule Drug Discovery
Mar 12, 2026
PRISM BioLab and Receptor.AI have signed a drug discovery collaboration to build an integrated, AI-navigated, physics-guided platform for designing orally available small molecules against intracellular protein–protein interactions, membrane...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.